CytoDyn Inc.
CytoDyn Inc. Fundamental Analysis
CytoDyn Inc. (CYDY) shows moderate financial fundamentals with a PE ratio of -9.51, profit margin of 6.56%, and ROE of 36.98%. The company generates $-0.0B in annual revenue with weak year-over-year growth of 0.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 50.6/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze CYDY's fundamental strength across five key dimensions:
Efficiency Score
WeakCYDY struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCYDY trades at attractive valuation levels.
Growth Score
ModerateCYDY shows steady but slowing expansion.
Financial Health Score
ModerateCYDY shows balanced financial health with some risks.
Profitability Score
WeakCYDY struggles to sustain strong margins.
Key Financial Metrics
Is CYDY Expensive or Cheap?
P/E Ratio
CYDY trades at -9.51 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CYDY's PEG of -6.12 indicates potential undervaluation.
Price to Book
The market values CytoDyn Inc. at -3.54 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -10.79 times EBITDA. This is generally considered low.
How Well Does CYDY Make Money?
Net Profit Margin
For every $100 in sales, CytoDyn Inc. keeps $6.56 as profit after all expenses.
Operating Margin
Core operations generate 2.49 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $36.98 in profit for every $100 of shareholder equity.
ROA
CytoDyn Inc. generates $-2.10 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
CytoDyn Inc. generates strong operating cash flow of $-17.91M, reflecting robust business health.
Free Cash Flow
CytoDyn Inc. generates strong free cash flow of $-17.91M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $-0.01 in free cash annually.
FCF Yield
CYDY converts -4.86% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-9.51
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-6.12
vs 25 benchmark
P/B Ratio
Price to book value ratio
-3.54
vs 25 benchmark
P/S Ratio
Price to sales ratio
-62.10
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-0.39
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.37
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.37
vs 25 benchmark
ROA
Return on assets percentage
-2.10
vs 25 benchmark
ROCE
Return on capital employed
0.46
vs 25 benchmark
How CYDY Stacks Against Its Sector Peers
| Metric | CYDY Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -9.51 | 28.23 | Better (Cheaper) |
| ROE | 36.98% | 737.00% | Weak |
| Net Margin | 655.73% | -46175.00% (disorted) | Strong |
| Debt/Equity | -0.39 | 0.35 | Strong (Low Leverage) |
| Current Ratio | 0.37 | 4.10 | Weak Liquidity |
| ROA | -209.73% | -17785.00% (disorted) | Weak |
CYDY outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews CytoDyn Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
75.11%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
93.89%
Industry Style: Defensive, Growth, Innovation
High Growth